A Phase 2 interventional study of Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection and Placebo 4 mL Solution for Injection in Multiple Sclerosis, Relapsing-Remitting, sponsored by University Hospital, Strasbourg, France. Recruiting at 5 sites in France. Open to male participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-06-29.
Sponsored by University Hospital, Strasbourg, France · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France — 9 open to participants now, 14 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · France.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, this one is the 62nd largest by planned enrollment of the 70 interventional ones that give a count, is one of 6 that started in 2019, is one of 12 in phase 2, reaches primary completion later than 9 of the 13 other live ones, and was the 59th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →9 of the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 40+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18–55
Rennes University Hospital · Sites in France
Ages 18–55
Centre d'Investigation Clinique et Technologique 805 · Sites in France
Ages 18–55 · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 6 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 154 across the 70 interventional studies, 499 across the 12 observational. Of the 65 that completed or were terminated, 28 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 82 have an industry lead sponsor. The 10 most frequent:
University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.
University Hospital, Strasbourg, France has 4 studies filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
6 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06663189Phase 3University Hospital, Strasbourg, FranceDisease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) | 2027-01 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT06330077Assistance Publique - Hôpitaux de ParisIfenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies in Multiple Sclerosis, Relapsing-Remitting with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Centra nervous system (CNF) damage in multiple sclerosis (MS), are mainly attributed to myelin destruction, axonal abnormalities and subsequent degeneration, and are responsible for serious deficiencies. Current therapies are focused on the treatment of inflammation with several types of anti-inflammatory agents. However, there is an urgent need for innovative therapies promoting neuroregeneration and particularly myelin repair.
It has been demonstrated that testosterone can act through neural androgen receptors to promote proliferation and differentiation of oligodendrocyte precursors into mature oligodendrocytes in a cuprizone-induced animal model of demyelination. The rare clinical trials on testosterone are mainly exploratory. Here, we sought to demonstrate an effect of testosterone supplementation in testosterone-deficient patients in a multicenter, randomized, parallel-group, double-blind, placebo-controlled phase 2 trial.
The main objective will be to determine the neuroprotective and remyelinating effects of testosterone using tensor diffusion imaging techniques and thalamic atrophy analyzes.
As secondary objectives, we would like to study the impact of testosterone supplementation on other conventional and unconventional MRI parameters and on clinical outcomes (cognition, fatigue, quality of life, impact on work / activity and anxiety / depression).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
"Treatment/Nebido®" arm: in this experimental arm, each patient will be injected intramuscularly with 1000 mg / 4 ml of testosterone undecanoate (Nebido®). Treatment will be injected at baseline, week 6, 18, 30, 42 and 54
Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection · Procedure: MRI · Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities · Behavioral: Assessment of disability
"Placebo" arm: In this arm, each patient will be injected intramuscularly with 4 ml of placebo solution. Placebo will be injected at baseline, week 6, 18, 30, 42 and 54
Drug: Placebo 4 mL Solution for Injection · Procedure: MRI · Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities · Behavioral: Assessment of disability
Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
EDSS (Baseline, week 30 and 66)
Change on MRI binary criterion combining thalamic atrophy and modification in transverse diffusivity of lesions
The primary endpoint is a binary criterion comparing the success rate in each treatment group, defined by thalamic atrophy lower than 0.5% and modification in transverse diffusivity of lesions lower than 0.5% per year compared between baseline and week 66 in each group.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of the number of T1 hypointense lesions as detected by conventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of the volume of T1 hypointense lesions as detected by conventional MRIconventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of the number of new or enlarged T2 lesions as detected by conventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of the volume of new or enlarged T2 lesions as detected by conventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of the total volume of hyper-intensity FLAIR lesion as detected by conventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of diffusion tensor imaging (NODDI) as detected by unconventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of quantitative magnetization transfer imaging (MPF) as detected by unconventional MRI
Efficacy will be assessed by comparing results between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of cognitive performance as measured by Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
BICAMS is a composite cognitive assessment tool comprising of the three components: Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II) and Brief visuospatial memory test- Revised (BVMT-R). Efficacy will be assessed by comparing the composite score between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Changes in quality of life as measured by the SF-36 questionnaire
SF-36 questionnaire is a 36-item Short Form survey designed to examine the perceived health status measured in eight health concepts. Answers to each question are scored and summed to produce raw scale scores for each health concept. Efficacy will be assessed by comparing scores between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Changes in quality of life related to health as measured by the EQ-5D-3L (European Quality of Life in 3 Dimensions) questionnaire.
EQ-5D-3L is a standardized instrument used as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. Efficacy will be assessed by comparing the composite scores between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Changes in work productivity and daily activities due to MS, as assessed by the WPAI:MS questionnaire (Work Productivity and Activity Impairment in MS).
WPAI questionnaire measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteeism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity. Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Changes in fatigue, measured by the Multidimensional Fatigue Impact Scale (MFIS)
MFIS is a 21-item questionnaire that assesses overall self-reported fatigue. Subjects rate agreement with a series of statements on a scale of 0 (rarely) to 4 (almost always), in context of their fatigue over the preceding four weeks. Total possible score of 84. Individuals with an MFIS score of \> 38 are considered to experience moderate to severe "fatigue". Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Changes in anxiety and depression as measured by the Hospital assessment for Anxiety and Depression Scale (HADS) questionnaire
HADS is a 14-item self-rating scale that assesses anxiety and depression. Each question is scored on a scale ranging from 0 to 3. Responses are summed to provide separate scores for anxiety and depression that range from 0 to 21. For each corresponding subscale, a total score of 0-7 equals normal, 8-10 equals borderline case, and 11-21 equals case. Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Evolution of disability measured MS specific Expanded Disability Status scale (EDSS)
EDSS measures disability status on a scale ranging from 0 to 10, in eight functional system scale: motor, sensory, cerebellar, brain stem, visual, mental, sphincter and other systems. The EDSS is formed on the score in each functional system; higher scores indicating more disability (0 = normal examination and 10= death from MS). Efficacy will be assessed by comparing score between the 2 groups and in each group between baseline, week 30 and week 66.
Time frame: At baseline, week 30 and week 66 (end of study)
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Safety of treatment will be followed by the number and type of adverse or severe adverse events (AE/SAE) throughout the protocol (from baseline to week 66)
Time frame: From Visit 0/baseline to end of study visit (66 weeks)
Plan to share: No
Started Oct 2019 (actual). Primary completion is estimated for Dec 2027, 98 months after the start.
Of 25 phase 2 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 98 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →
University Hospital, Strasbourg, France →